For John Tozzi's latest contributions to The Japan Times, see below:
Private insurers in the U.S. have mostly declined to cover Aduhelm, saying they need more proof of its efficacy and that benefits outweigh risks like brain swelling.
U.S. hospitals are struggling to get the workers they need to treat patients through the winter’s COVID-19 surge as the virus collides with a historically tight labor market.
The congressional inquiry adds to pressure on the U.S. agency charged with regulating products that account for one-fifth of consumer spending.
Does aspartame cause cancer? You've probably heard that it might. And PepsiCo removing the artificial sweetener from Diet Pepsi suggests there's something iffy about it. New Diet Pepsi cans boast that the beverage is "now aspartame free," a statement probably meant to placate consumers ...
Growing up poor has long been linked to lower academic test scores. And there's now mounting evidence that it's partly because kids can suffer real physical consequences from low family incomes, including brains that are less equipped to learn. An analysis of hundreds of magnetic ...
